Ecommerce / Retail · Deep dive

Chewy

Ryan Cohen's Autoship machine sold to PetSmart for $3.35B in 2017, IPO'd in 2019, and now does $12.6B a year — yet the stock trades below its 2019 debut as BC Partners still holds the votes.

well positioned

An 84%-Autoship recurring-revenue base, a genuine customer-service moat, and durable free cash flow make Chewy the structural winner in US pet ecommerce — the risks are the sponsor overhang and an unproven, capital-hungry vet-clinic bet, not the core franchise.

My take ★★ Very interesting ★ Interesting − Maybe ✗ Not interesting

Snapshot

Chewy is the largest online-only pet retailer in the US, selling food, supplies, medication and, increasingly, veterinary care to roughly 21.5 million active customers. Fiscal 2025 net sales reached $12.60 billion; Q1 fiscal 2026 net sales grew 7.7% to $3.36 billion with net income of $94.8 million (company release, June 10, 2026). Its defining feature is Autoship, a recurring-delivery subscription that was 84.4% of net sales that quarter — a consumer retailer that is effectively a subscription business. Yet the stock trades near $21 (July 10, 2026), below its 2019 IPO price and roughly half its 52-week high, weighed down by decelerating growth, a capital-hungry vet-clinic push, and the shadow of PE owner BC Partners, which still controls ~88% of the vote.

Founding story

Chewy began in 2011 in Dania Beach, Florida, when Ryan Cohen — a 25-year-old Montreal entrepreneur with an affiliate-marketing background and no retail experience — teamed with engineer Michael Day. The thesis was contrarian: Pets.com had failed not because pet owners wouldn’t buy online but because logistics and service were broken. Cohen bet that nailing next-day delivery and treating service as the product would turn emotional, recurring pet spend into fierce loyalty. Day built the platform and the Autoship engine; Cohen obsessed over the phones, insisting on human, 24/7 support.

It worked. By 2017 Chewy did roughly $2 billion in revenue with an estimated 51% of US online pet-food sales. Cohen had raised $236 million of venture capital across five rounds (2013-2016), Volition Capital the first check, and was preparing to IPO when PetSmart — controlled by a BC Partners-led consortium — offered $3.35 billion all cash. He took it in April 2017, then the largest ecommerce acquisition ever, ran Chewy independently, and left in 2018 to become a meme-stock celebrity via GameStop.

The ownership wrinkle still defines the company. PetSmart — and therefore BC Partners — took Chewy public in June 2019 but kept the majority of shares and super-voting Class B stock: as of mid-2026 BC Partners held roughly 46% of shares but ~88% of voting power. Chewy is a controlled company run by professional management, but its ultimate owner is a PE sponsor steadily selling down a nine-year-old position.

How it works

Mechanically, Chewy is a subscription-commerce and fulfillment operation dressed as a retailer. A customer sets up Autoship — a product on a chosen cadence — for a recurring discount (~5%, up to 35% on a first order) with automatic reorders. That converts one-off buyers into an annuity: 84.4% of Q1 fiscal 2026 net sales came from Autoship customers, up from roughly two-thirds at IPO, and recurring demand forecasts cleanly, letting Chewy position inventory tightly.

Physically, orders flow through a national network of increasingly automated fulfillment centers, plus dedicated facilities for the pharmacy and bulky goods. The pharmacy is a hard-to-replicate asset: a licensed veterinary pharmacy that verifies prescriptions with vets and ships regulated medication, making Chewy Pharmacy the top online pet pharmacy in the US.

The service layer is the moat. Chewy’s care teams do things that look uneconomic in isolation — hand-painted pet portraits, and famously flowers and a sympathy card when a customer’s pet dies — cheap relative to the retention and word-of-mouth they generate, and the source of Chewy’s unusual brand affection for a commodity retailer.

Product and business overview

Core retail. Food, treats, toys, litter, crates, beds and health products across dogs, cats and smaller species — the recurring-consumables base Autoship monetizes.

Private brands. Frisco (hard goods), American Journey (premium food), Tylee and others, recently consolidated under a “Chewy Made” umbrella. Private label reached roughly 30% of sales by 2024 (Store Brands) and carries higher margin than national brands — a key gross-margin lever.

Chewy Pharmacy. Prescription and OTC medication, compounded drugs, and a growing specialty book; the highest-value, stickiest customers.

Chewy Health. The new growth vector: the pharmacy, tele-triage (“Connect with a Vet”), CarePlus insurance and wellness plans, and — the capital-intensive bet — Chewy Vet Care (CVC) physical clinics. CVC reached 18 owned clinics across five states in fiscal 2025; Chewy agreed to acquire Modern Animal (29 clinics), lifting the footprint toward 47 pending approval, and bought equestrian retailer SmartPak (~$175M).

Business model and pricing

Chewy has the economics of a low-gross-margin, high-repeat retailer, not a software platform. Consolidated gross margin was 29.8% in fiscal 2025 (up from 29.2% in fiscal 2024) on private-brand mix, ads and pharmacy — a climb from the low-20s at IPO. The model’s power is lifetime value, not margin per order: Autoship’s 84% share compounds the base, and net sales per active customer (NSPAC) rises as customers add pharmacy and health spend. Management flagged a near-term NSPAC headwind in June 2026 as value-seeking customers pull back on premiumization — a real signal given APPA’s finding that 22% of owners cut pet spending in 2025.

The strategic question sits below the line. CVC customers are ~40% new to Chewy and generate roughly $900 of first-year NSPAC, far above the base — the thesis being that owning the vet visit captures the highest-intent moment in pet spend. But clinics are real estate, staffing and equipment: cash fell from ~$860M to ~$485M in one quarter of 2026 amid buybacks and SmartPak, with ~$600M of term debt added. A net-cash retailer is becoming a leveraged M&A operator.

Traction over time

Read three lines. Growth decelerated from pandemic-era 40%+ to high-single digits — and stripping acquired SmartPak and Modern Animal revenue, one analyst pegged fiscal-2026 organic growth nearer ~5.7%. Active customers stalled and dipped after the 2020-21 boom before recovering to 21.5 million, so growth now comes mostly from getting more per customer, not adding customers. But profitability turned: adjusted EBITDA hit record levels, net margin reached 2.8% in Q1 fiscal 2026 (up 80bps), and free cash flow is consistent. The story shifted from land-grab to profitable compounding.

Market analysis

The US pet industry reached $158 billion in 2025 (+3.7%) and is projected at roughly $165 billion in 2026 (APPA 2026 State of the Industry, May 2026), ~2% of growth from inflation. Some 95 million US households own a pet, and dog ownership rose from 51% of households in 2024 to 53% in 2025. The structural tailwind is pet humanization — owners spending on premium food, health and services — which favors the categories (pharmacy, vet care, insurance) Chewy is entering.

Two counter-currents matter. Pet ecommerce penetration is now high and maturing, so the fight becomes share-of-wallet among Amazon, Walmart, Chewy and Petco rather than online-versus-store. And value-seeking is rising — 22% of owners spent less on pets in 2025 — shifting mix toward essentials and away from the discretionary attach that lifts NSPAC. Chewy’s market genuinely expands if it wins health and vet care, since that slice of the $158B is large and largely offline — but that is exactly where it is least proven and most capital-exposed.

Competitive intel

The named set sits in the competitor table; the structural read is that Chewy wins the specialist-ecommerce lane and is squeezed at both ends. Amazon owns logistics, Prime and price on commodity kibble, and panel data suggests it captured much of the churn from both Chewy and Petco in 2024-25. Walmart takes the trading-down customer; Temu and Shein nibble discretionary hard goods that carry Chewy’s better margins. On the other flank, Chewy’s push into physical vet care pits it against Mars (Banfield, BluePearl, VCA) and other well-capitalized networks that spent a decade consolidating the space.

The most telling comparison is Petco: same category, opposite trajectory. Petco’s ~$6.1B revenue shrank in the year to February 2025, it posted losses, its stock cratered from its 2021 IPO, and it paused vet-hospital construction to 2027 — and its one edge, in-person services, is exactly the ground Chewy now invades with CVC. Chewy is the healthiest pure pet retailer standing, but “healthiest in a category being raided by Amazon” is the honest frame, not “unassailable.”

History and evolution

• 2011 — Ryan Cohen and Michael Day found Chewy in Dania Beach, FL.
• 2013-2016 — Raises $236M across five rounds (Volition, Greenspring, Verlinvest, BlackRock); Autoship and next-day delivery drive rapid share gains.
• April 2017 — PetSmart (BC Partners consortium) buys Chewy for $3.35B, the largest ecommerce acquisition on record at the time.
• 2018 — Cohen departs; ex-Amazon executive Sumit Singh becomes CEO.
• June 2019 — IPO on NYSE at $22/share, raising ~$1.02B; opens up 64% at $36. PetSmart retains control via dual-class shares.
• 2020-2021 — Pandemic boom: sales jump to ~$7.15B then ~$8.89B; active customers pass 20M; stock spikes above a $40B valuation.
• 2022-2024 — Normalization; growth slows to single digits; focus shifts to margin, private brands and free cash flow. Canada launch in 2023. June 2024 $500M buyback from a BC Partners affiliate; Keith Gill briefly discloses a stake, echoing Cohen’s GameStop saga.
• 2023-2025 — Chewy Vet Care launches, reaching 18 owned clinics; CarePlus insurance and Connect-with-a-Vet build out Chewy Health.
• 2026 — Agrees to buy Modern Animal (29 clinics) and SmartPak (~$175M); adds ~$600M term debt; Q1 fiscal 2026 (June 10) net sales $3.36B, net income $94.8M. Stock drifts to ~$21 as analysts cut targets.

What people say

The case for. Chewy’s customer-service reputation is a documented, viral phenomenon, not marketing gloss. Stories of the company refunding an unopened bag of food after a pet’s death, then sending flowers with a personally signed card, have circulated for years (one such post drew over 700,000 likes, per Apartment Therapy); others report hand-painted portraits of deceased pets. Reddit’s pet communities, hostile to most retailers, stay broadly loyal on service and hassle-free returns. Sell-side sentiment respects the fundamentals — an 84% Autoship base, expanding gross margin, record adjusted EBITDA, durable free cash flow. Bulls argue the health and vet push broadens the addressable market at the highest-intent point of pet spend, and that at ~$21 the stock discounts most of the bad news. Employees rate the company around 3.5 on Glassdoor for a genuine customer-first culture.

The complaints. The love is not universal and the operational reviews are harsh. Chewy’s Trustpilot score sits around 2.1 stars, heavy on one-star reviews, and the BBB has logged over 1,600 complaints in three years. Recurring themes: Autoship billing errors and double-charges, difficulty cancelling, refund runarounds — one customer described being charged over $400 for seven boxes shipped in error and struggling to reverse it. Pharmacy complaints center on the clunky prescription process and slow weekend shipping on urgent medication. Warehouse workers rate Chewy about 2.5 on Glassdoor — well below the corporate average — citing short-notice mandatory overtime, heavy lifting, worn equipment and hot facilities, a jarring gap for a company famed for care. On the stock, the bear case is specific: a P/E north of 50x leaves no room for a margin miss; the vet rollout looks capital-inconsistent (scaling toward ~60 clinics while quarterly capex ran only ~$38M); organic growth is decelerating toward ~5.7%; and the balance sheet is levering up. Analysts cut targets from the high-$30s toward ~$31, with bear cases at $15-$20.

Outlook: well positioned or at risk?

Well positioned — with two caveats that keep it from being a clean call.

The core franchise is a structural winner. A retailer where 84% of sales are effectively subscriptions, gross margin is climbing through private brands and ads, and free cash flow is durable is a fundamentally better business than any brick-and-mortar pet retailer — Petco’s slow-motion collapse is the control experiment. The service moat is genuine and self-reinforcing, lowering churn and acquisition cost in a category built on emotion. In a US pet market growing ~4% a year, Chewy is the highest-quality way to own pet ecommerce, and at ~$21 the market prices in real pessimism.

The first caveat is the sponsor: BC Partners is nine years into a hold and steadily selling, and its dual-class control (~88% of the vote on ~46% of shares) leaves minority holders with an overhang and governance they can’t influence. Continued selldowns cap the stock even as fundamentals improve. The second is the vet-clinic bet. Chewy Vet Care is strategically logical — it captures the highest-value moment in pet spend and the ~$900 first-year NSPAC is compelling — but it turns an asset-light, net-cash compounder into a capital-intensive, now-levered operator facing Mars-scale incumbents, and the capex math has drawn legitimate skepticism. If clinics scale profitably, Chewy re-rates; if they become a cash sink, the pivot gets punished.

Net: the base compounds and the moat is real, so the verdict is well positioned — but the upside is gated by BC Partners’ selling and an unproven vet-care bet. This is a good business with an ownership problem and an expensive new habit, not a broken one.

How a challenger would attack it

Attack the gap between the brand and the operation. Chewy’s marketing moat is sympathy flowers; its operational reality is a 2.1-star Trustpilot, 1,600+ BBB complaints, and a complaint file dominated by one theme — Autoship billing errors, double-charges, and cancellation friction. The subscription engine that produces 84% of net sales is also the single largest source of customer rage, which means the attack vector is a pet subscription that is radically transparent: pre-charge notifications, one-tap skip and cancel, no seven-boxes-shipped-in-error failure modes. Pair that with the pharmacy complaints — clunky prescription verification, slow weekend shipping on urgent meds — and a challenger builds an Rx-first pet company with same-day courier delivery on medication in metro areas, hitting Chewy where its customers are sickest and stickiest. The price flank is already being run by others (Walmart on kibble, Temu on hard goods), so the differentiated opening is premium service actually delivered, not promised. Timing helps: Chewy is distracted — levering up ~$600M for clinics and SmartPak, cash halved in a quarter, management fighting an NSPAC headwind — and a controlled company optimizing for BC Partners’ exit is slow to reinvest in unsexy billing UX.

Same playbook, new buyer

The Autoship playbook — recurring consumables plus pharmacy plus emotional service in a humanized category — maps onto buyers Chewy will not chase. The clearest is the horse: Chewy just paid ~$175M for SmartPak precisely because equestrian is a high-spend, underserved vertical, but SmartPak is a bolt-on, not a rebuild, and the same logic extends to backyard livestock, reptiles, and birds — categories with devoted owners, specialist consumables, and no subscription-native retailer. Second is geography: Chewy’s only international move is Canada (2023); the UK, Germany, and Japan have Zooplus-style generalists but nothing pairing a licensed pet pharmacy with Autoship economics, and Chewy’s clinic-heavy, debt-carrying balance sheet forecloses overseas expansion for years. Third is the senior-pet and chronic-condition segment: recurring prescription diets, compounded meds, and tele-triage bundled as a care subscription — the highest-LTV slice of the base, currently served as an aisle rather than a product. The incumbent won’t follow because every incremental dollar is committed to the CVC clinic rollout, and its controlling shareholder is nine years into a sale, not an expansion.

Sources and further reading

• Chewy Announces First Quarter 2026 Financial Results — Chewy, Inc., June 10, 2026. Q1 net sales, Autoship, active customers.
• Chewy.com prices IPO at $22 a share — CNBC, June 13, 2019. IPO terms and ~$8.8B valuation.
• Meet the Young Founders of Chewy.com — Volition Capital, 2017. Early venture rounds and the $3.35B sale.
• Chewy expands clinic ownership with Modern Animal purchase — AVMA, 2026, and Launch of Chewy Vet Care — Business Wire, December 14, 2023. CVC rollout.
• BC Partners Sells Stake; Chewy Announces Buyback — StockTitan / CHWY 8-K, 2024-2025. Sponsor selldown, dual-class control.
• Petco and Chewy’s customer losses fuel Amazon’s growth — GlobalPETS, 2025. Competitive share data.
• U.S. Pet Industry Reaches $158 Billion in 2025 — APPA 2026 State of the Industry, May 2026. TAM and trends.
• CHWY Stock After the Drop: Valuation, Risks & What Comes Next — MEXC, 2026. Bear case, capex skepticism, price targets.
• Chewy BBB Complaints and Chewy on Trustpilot — accessed July 2026. Complaint themes.